Milk thistle: Is there a role for its use as an adjunct therapy in patients with cancer?

Journal of Alternative and Complementary Medicine

Volumn 9, Issue 3, 2003, Pages 411-416

  Ladas, Elena J ^a   Kelly, Kara M ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Columbia Univ Coll Physic/Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; CANCER ADJUVANT THERAPY; CANCER PATIENT; DNA SYNTHESIS INHIBITION; FIRST PASS EFFECT; HUMAN; LIPID PEROXIDATION; LIVER DYSFUNCTION; LIVER TOXICITY; MENTAL STRESS; PATIENT CARE; PRIORITY JOURNAL; PROBABILITY; PSYCHOLOGICAL ASPECT; QUALITY CONTROL; REVIEW; SILYBUM MARIANUM;

EID: 0038012718     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/107555303765551633     Document Type: Review

References (46)

1. Abu-Realh MH, Magwood G, Narayan MC, Rupprecht C, Suraci M. The use of complementary therapies by cancer patients. Nurs Connections 1996;9:3-12.
2. Albrecht M, Frerick H. Therapy of toxic liver pathologies with Legalon. Z Klin Medicine 1992;47:87-92.
3. Altorjay I, Dalmi L, Sari B, Imre S, Balla G. The effect of silibinin (Legalon) on the free radical scavenger mechanisms of human erythrocytes in vitro. Acta Physiol Hung 1992;80:375-380.
4. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Weltc K, Stanulla M. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000;10:715-726.
5. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15:333-338.
6. Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: Comparison with silymarin. Cancer Lett 1999;147:77-84.
7. Bosisio E, Benelli C, Pirola O. Effect of the flavanolignans of Silybum marianum L on lipid perioxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res 1992;25:147-154.
8. Campos R, Garrido A, Guerra R, Valenzuela A. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 1989;55:417-419.
9. Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
10. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996;23:749-754.
11. Farghali H, Kamenikova L, Hynie S, Kmonickova E. Silymarin effects on intracellular calcium and cytotoxicity: A study in perfused rat hepatocytes after oxidative stress injury. Pharmacol Res 2000;41:231-237.
12. Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 1997;15:1560-1566.
13. Faw C, Ballentine R, Ballentine L, vanEys J. Unproved cancer remedies: A survey of use in pediatric outpatients. JAMA 1977;238:1536-1538.
14. Ferenci P, Dragosies B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver: J Hepatol 1989;9:105-113.
15. Fleming T, ed. PDR for Herbal Medicine. Montvale, NJ: Medical Economics, 2000:516-520.
16. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139-143.
17. Friedman T, Slayton WB, Allen LS, Pollock BH, Dumont-Driscoll M, Mehta P, Graham-Pole J. Use of alternative therapies for children with cancer. Pediatrics 1997;100:E1.
18. Garrido A, Arancibia C, Campos R, Valenzuela A. Acetaminophen does not induce oxidative stress in isolated rat hepatocytes: Its probable antioxidant effect is potentiated by the flavonoid silybin. Pharmacol Toxicol 1991;69:9-12.
19. Hernandez R, Nazar E. Effect of silymarin in intrahepatic cholestasis of pregnancy. Revista Chilena de Obstetricia y Ginecologia. 1982;47:22-29.
20. Hohn D, Melnick J, Stagg R, Altman D, Friedman M, Ignoffo R, Ferrell L, Lewis B. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985;3:98-102.
21. Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 1983;2:183-195.
22. Huizing MT, Misser VH, Pieters RC, Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH. Taxanes: A new class of antitumor agents. Cancer Invest 1995;13:381-404.
23. Invernizzi R, Bernuzzi S, Ciani D, Ascari E. Silymarine during maintenance therapy of acute promyelocytic leukemia. Haematologica 1993;78:340-341.
24. Kelly KM, Jacobson JS, Kennedy DD, Braudt SM, Mallick M, Weiner MA. Use of unconventional therapies by children with cancer at an urban medical center. J Pediatr Hematol Oncol 2000;22:412-416.
25. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001;6:162-176.
26. Koch HP, Loffler E. Influence of silymarin and some flavonoids on lipid peroxidation in human platelets. Methods Find Exp Clin Pharmacol 1985;7:13-18.
27. Lerner IJ, Kennedy BJ. The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin 1992;42:181-191.
28. Letteron P, Labbe G, Degott C, Berson A, Fromenty B, Delaforge M, Larrey D, Pessayre D. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice: Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem Pharmacol 1990;39:2027-2034.
29. Maskarinec G, Shumay DM, Kaki H, Gotay CC. Ethnic differences in complementary and alternative medicine use among cancer patients. J Altern Complement Med 2000;6:531-538.
30. Mira L, Silva M, Manso CF. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1987;48:753-759.
31. Mira MI, Azevedo MS, Manso C. The neutralization of hydroxyl radical by silibin, sorbinil and hendazac: Free Radic Res Commun 1997;4:125-129.
32. National Cancer Institute. Online document at www.seer.cancer.gov/2002.
33. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-2514.
34. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver: A double-blind controlled study. Scand J Gastroenterol 1982;17:517-521.
35. Scambia G, De Vincenzo R, Ranelletti FO, Panici PB, Ferrandina G, D'Agostino G, Fattorossi A, Bombardelli E, Mancuso S. Antiproliferative effect of silybin on gynaecological malignancies: Synergism with cisplatin and doxorubicin. Eur J Cancer 1996;32A:877-882.
36. Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1991;8:301-312.
37. Sonnenbichler J, Goldberg M, Hane L, Madubunyi I, Vogl S, Zetl I. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers: Non-response in hepatoma and other malignant cell lines. Biochem Pharmacol 1986;35:538-541.
38. Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, Parks S, Steinberg SM, Wootton JC. Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 2000;27:623-630.
39. Sparber A, Wootton JC. Surveys of complementary and alternative medicine: Part II. Use of alternative and complementary cancer therapies. J Altern Complement Med 2001;7:281-287.
40. Stork LC, Sather H, Hutchinson RJ, Broxson EH, Matloub Y, Yanofsky R, Masterson M, Sorrell A, La M, Wells L, Blake M, Gaynon BS. Comparison of mercaptopurine with thioguanine and IT methotrexate with IT "tripics" in children with SR-ALL: Results of CCG-1952 [abstr. 585]. Blood 2002;100(11).
41. Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med 1989;55:420-422.
42. Valenzuela A, Guerra R, Garrido A. Silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis. Planta Med 1987;53:402-405.
43. Valenzuela A, Guerra R, Videla LA. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: Comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med 1986;438-440.
44. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: Implications in cancer chemoprevention. Carcinogenesis 1999;20:2101-2108.
45. Zhao J, Sharma Y, Agarwal R. Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1alpha expression in SENCAR mouse epidermis: Implications in the prevention of stage 1 tumor promotion. Mol Carcinog 1999;26:321-333.
46. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proc Natl Acad Sci USA 1999;96:7490-7495.